Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Research & Development (2023 - 2025)

Historic Research & Development for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $9.3 million.

  • Tonix Pharmaceuticals Holding's Research & Development rose 192.01% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year decrease of 2654.58%. This contributed to the annual value of $40.0 million for FY2024, which is 5387.23% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Research & Development of $9.3 million as of Q3 2025, which was up 192.01% from $10.8 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Research & Development high stood at $21.0 million for Q3 2023, and its period low was $7.4 million during Q1 2025.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Research & Development averaged around $11.7 million, with its median value being $9.7 million (2024).
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Research & Development crashed by 5670.31% in 2024 and then soared by 1156.94% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Research & Development (Quarter) stood at $17.1 million in 2023, then tumbled by 51.54% to $8.3 million in 2024, then rose by 11.96% to $9.3 million in 2025.
  • Its Research & Development was $9.3 million in Q3 2025, compared to $10.8 million in Q2 2025 and $7.4 million in Q1 2025.